# Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine

> **NCT02846519** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 66 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Esketamine
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT02846519
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-26
- **Primary completion:** 2016-05-28
- **Final completion:** 2016-05-28
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02846519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02846519, "Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02846519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*